Table 1.
Study | age | Size (n) | Daily EPA/DHA dose (g)1 | Control agent | duration | Effect seen |
---|---|---|---|---|---|---|
Hodge, 1998 | 8–12 | 39 | .72/.036 | Safflower/Sunflower | 6 months | No |
Broughton, 1997 | 19–25 | 19 | -- | -- | 1 month | Reduced AHR |
Arm, 1988 | 15–42 | 25 | 3.2/2.2 | Olive oil | 10 weeks | Reduced inflammation |
Arm, 1989 | 15–42 | 17 | 3.2/2.2 | Olive oil | 10 weeks | Lung function |
Thien, 1993 | 15–65 | 25 | 3.2/2.2 | Olive oil | 6 months | No |
Surette, 2003 | 18–56 | 43 | .5–.75/-- | -- | 4 weeks | Reduced LT production |
Emelyanov, 2002 | 18–56 | 23 | Combined | Olive oil | 8 weeks | Reduced symptoms |
Mickleborough, 2006 | Mean = 23 | 16 | 3.2/2.0 | Olive oil | 3 weeks | Lung function |
AHR – airway hyperresponsiveness, LT – leukotriene.
Institute of Medicine’s adequate intake for omega-3 polyunsaturated fatty acids is 1.1 and 1.6 grams/day for females and males, respectively (IOM report, 2002). A typical serving of Salmon contains just less than 1 gram of EPA + DHA.